BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$19.0M

Filings

100

Firms Hired

Active Period

2001–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$650,000	3	1
2025	$940,000	4	1
2024	$820,000	4	1
2023	$1,190,000	4	1
2022	$340,000	4	1
2021	$230,000	4	1
2020	$430,000	4	1
2019	$1,330,000	4	1
2018	$1,170,000	5	1
2017	$2,808,342	7	1
2016	$740,000	4	1
2015	$1,650,000	7	1
2014	$720,000	6	1
2013	$430,000	5	1
2012	$1,350,000	6	1
2011	$250,000	4	1
2010	$670,000	4	1
2009	$210,000	6	1
2008	$510,000	4	1
2007	$800,000	2	1
2006	$340,000	2	1
2004	$760,000	2	1
2003	$300,000	2	1
2002	$240,000	2	1
2001	$160,000	1	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)	$19,038,342	100

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	99
SENATE	99
Health & Human Services, Dept of (HHS)	14
Defense, Dept of (DOD)	10
Food & Drug Administration (FDA)	7
Centers For Medicare and Medicaid Services (CMS)	6
Natl Institutes of Health (NIH)	5
Health Resources & Services Administration (HRSA)	1
Office of Personnel Management (OPM)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Budget/Appropriations	Budget/Appropriations	98
Health Issues	Health Issues	92
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	20
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	7
Medicare/Medicaid	Medicare/Medicaid	7
Small Business	Small Business	4
Economics/Economic Development	Economics/Economic Development	2
Insurance	Insurance	1
Government Issues	Government Issues	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 10227119th Congress

INSULIN Act of 2026

2026 · third_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 10227, the INSULIN Act and Issues pertaining to FDA modernization; S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to grant funding for the Special Diabetes Program; Issues pertaining to pending legislation for reclassification of deceased donor islet cells.

Client expense: $150,000 · Firm income: —

Matched citations: H.R. 10227

H.R. 8018119th Congress

ISLET Act

2026 · third_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 10227, the INSULIN Act and Issues pertaining to FDA modernization; S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to grant funding for the Special Diabetes Program; Issues pertaining to pending legislation for reclassification of deceased donor islet cells.

Client expense: $150,000 · Firm income: —

Matched citations: H.R. 8018

H.R. 8646119th Congress

Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027

2026 · third_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027; H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; Issues pertaining to NIH & FDA funding.

Client expense: $150,000 · Firm income: —

Matched citations: H.R. 8646

H.R. 9000119th Congress

SCREEN for Type 1 Diabetes Act of 2026

2026 · third_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 10227, the INSULIN Act and Issues pertaining to FDA modernization; S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to grant funding for the Special Diabetes Program; Issues pertaining to pending legislation for reclassification of deceased donor islet cells.

Client expense: $150,000 · Firm income: —

Matched citations: H.R. 9000

Show 21 more cited filings

H.R. 9620119th Congress

Military Next-Gen Collision Avoidance Act of 2026

2026 · third_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027; H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; Issues pertaining to NIH & FDA funding.

Client expense: $150,000 · Firm income: —

Matched citations: H.R. 9620

S. 4189119th Congress

INSULIN Act of 2026

2026 · third_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 10227, the INSULIN Act and Issues pertaining to FDA modernization; S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to grant funding for the Special Diabetes Program; Issues pertaining to pending legislation for reclassification of deceased donor islet cells.

Client expense: $150,000 · Firm income: —

Matched citations: S. 4189

S. 4612119th Congress

SCREEN for Type 1 Diabetes Act of 2026

2026 · third_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 10227, the INSULIN Act and Issues pertaining to FDA modernization; S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to grant funding for the Special Diabetes Program; Issues pertaining to pending legislation for reclassification of deceased donor islet cells.

Client expense: $150,000 · Firm income: —

Matched citations: S. 4612

H.R. 5467119th Congress

PAAT Act

2026 · second_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 4612, the SCREEN for T1D Act; H.R. 5467 - the Patient Access to Autoimmune Treatments Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to Special Diabetes Program.

Client expense: $220,000 · Firm income: —

Matched citations: H.R. 5467

H.R. 8018119th Congress

ISLET Act

2026 · second_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 4612, the SCREEN for T1D Act; H.R. 5467 - the Patient Access to Autoimmune Treatments Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to Special Diabetes Program.

Client expense: $220,000 · Firm income: —

Matched citations: H.R. 8018

H.R. 8646119th Congress

Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027

2026 · second_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027; H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; Issues pertaining to NIH & FDA funding.

Client expense: $220,000 · Firm income: —

Matched citations: H.R. 8646

H.R. 9000119th Congress

SCREEN for Type 1 Diabetes Act of 2026

2026 · second_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 4612, the SCREEN for T1D Act; H.R. 5467 - the Patient Access to Autoimmune Treatments Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to Special Diabetes Program.

Client expense: $220,000 · Firm income: —

Matched citations: H.R. 9000

H.R. 9620119th Congress

Military Next-Gen Collision Avoidance Act of 2026

2026 · second_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027; H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; Issues pertaining to NIH & FDA funding.

Client expense: $220,000 · Firm income: —

Matched citations: H.R. 9620

S. 4189119th Congress

INSULIN Act of 2026

2026 · second_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 4612, the SCREEN for T1D Act; H.R. 5467 - the Patient Access to Autoimmune Treatments Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to Special Diabetes Program.

Client expense: $220,000 · Firm income: —

Matched citations: S. 4189

S. 4612119th Congress

SCREEN for Type 1 Diabetes Act of 2026

2026 · second_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 4612, the SCREEN for T1D Act; H.R. 5467 - the Patient Access to Autoimmune Treatments Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to Special Diabetes Program.

Client expense: $220,000 · Firm income: —

Matched citations: S. 4612

H.R. 5461119th Congress

Special Diabetes Program Reauthorization Act of 2025

2026 · first_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 S. 3064 - the Relief of Chronic Disease Pain Act of 2026 S. 4189 - the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026 H.R. 5467 - the Patient Access to Autoimmune Treatments Act S. 3105 / H.R. 8018 - the Increase Support for Life-saving Endocrine Transplantation Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to NIH/FDA funding Issues pertaining to screening and early detection

Client expense: $280,000 · Firm income: —

Matched citations: H.R. 5461

H.R. 5467119th Congress

PAAT Act

2026 · first_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 S. 3064 - the Relief of Chronic Disease Pain Act of 2026 S. 4189 - the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026 H.R. 5467 - the Patient Access to Autoimmune Treatments Act S. 3105 / H.R. 8018 - the Increase Support for Life-saving Endocrine Transplantation Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to NIH/FDA funding Issues pertaining to screening and early detection

Client expense: $280,000 · Firm income: —

Matched citations: H.R. 5467

H.R. 7148119th Congress

Consolidated Appropriations Act, 2026

2026 · first_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

H.R.7148 - Consolidated Appropriations Act, 2026

Client expense: $280,000 · Firm income: —

Matched citations: H.R.7148

H.R. 8018119th Congress

ISLET Act

2026 · first_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 S. 3064 - the Relief of Chronic Disease Pain Act of 2026 S. 4189 - the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026 H.R. 5467 - the Patient Access to Autoimmune Treatments Act S. 3105 / H.R. 8018 - the Increase Support for Life-saving Endocrine Transplantation Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to NIH/FDA funding Issues pertaining to screening and early detection

Client expense: $280,000 · Firm income: —

Matched citations: H.R. 8018

S. 2211119th Congress

Special Diabetes Program Reauthorization Act of 2025

2026 · first_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 S. 3064 - the Relief of Chronic Disease Pain Act of 2026 S. 4189 - the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026 H.R. 5467 - the Patient Access to Autoimmune Treatments Act S. 3105 / H.R. 8018 - the Increase Support for Life-saving Endocrine Transplantation Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to NIH/FDA funding Issues pertaining to screening and early detection

Client expense: $280,000 · Firm income: —

Matched citations: S. 2211

S. 3064119th Congress

Relief of Chronic Pain Act of 2025

2026 · first_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 S. 3064 - the Relief of Chronic Disease Pain Act of 2026 S. 4189 - the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026 H.R. 5467 - the Patient Access to Autoimmune Treatments Act S. 3105 / H.R. 8018 - the Increase Support for Life-saving Endocrine Transplantation Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to NIH/FDA funding Issues pertaining to screening and early detection

Client expense: $280,000 · Firm income: —

Matched citations: S. 3064

S. 3105119th Congress

ISLET Act

2026 · first_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 S. 3064 - the Relief of Chronic Disease Pain Act of 2026 S. 4189 - the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026 H.R. 5467 - the Patient Access to Autoimmune Treatments Act S. 3105 / H.R. 8018 - the Increase Support for Life-saving Endocrine Transplantation Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to NIH/FDA funding Issues pertaining to screening and early detection

Client expense: $280,000 · Firm income: —

Matched citations: S. 3105

S. 4189119th Congress

INSULIN Act of 2026

2026 · first_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 S. 3064 - the Relief of Chronic Disease Pain Act of 2026 S. 4189 - the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026 H.R. 5467 - the Patient Access to Autoimmune Treatments Act S. 3105 / H.R. 8018 - the Increase Support for Life-saving Endocrine Transplantation Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to NIH/FDA funding Issues pertaining to screening and early detection

Client expense: $280,000 · Firm income: —

Matched citations: S. 4189

H.R. 5304119th Congress

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026

2025 · fourth_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 - Continuing Appropriations and Extensions Act of 2026

Client expense: $290,000 · Firm income: —

Matched citations: H.R. 5304

H.R. 5371119th Congress

Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026

2025 · fourth_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 - Continuing Appropriations and Extensions Act of 2026

Client expense: $290,000 · Firm income: —

Matched citations: H.R. 5371

H.R. 5461119th Congress

Special Diabetes Program Reauthorization Act of 2025

2025 · fourth_quarter · Firm: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Open original LDA filing ↗

Cited source text and reported amounts

S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians H.R. 5467 - Patient Access to Autoimmune Treatments Act Issues pertaining to NIH research Issues pertaining to prior authorization Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to insulin affordability

Client expense: $290,000 · Firm income: —

Matched citations: H.R. 5461

Source: Senate LDA

BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.) — Lobbying Disclosure | Poliscope